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Sarcoidosis is a multiorgan inflammatory disorder with heritability estimates up to 66%. 
Previous studies have shown the major histocompatibility complex (MHC) region to be 
associated with sarcoidosis, suggesting a functional role for antigen-presenting mole-
cules and immune mediators in the disease pathogenesis. To detect variants predis-
posing to sarcoidosis and to identify genetic differences between patient subgroups, we 
studied four genes in the MHC Class III region (LTA, TNF, AGER, BTNL2) and HLA-DRA 
with tag-SNPs and their relation to HLA-DRB1 alleles. We present results from a joint 
analysis of four study populations (Finnish, Swedish, Dutch, and Czech). Patients with 
sarcoidosis (n =  805) were further subdivided based on the disease activity and the 
presence of Löfgren’s syndrome. In a joint analysis, seven SNPs were associated with 
non-Löfgren sarcoidosis (NL; the strongest association with rs3177928, P = 1.79E−07, 
OR =  1.9) and eight with Löfgren’s syndrome [Löfgren syndrome (LS); the strongest 
association with rs3129843, P = 3.44E−12, OR = 3.4] when compared with healthy 
controls (n =  870). Five SNPs were associated with sarcoidosis disease course (the 
strongest association with rs3177928, P = 0.003, OR = 1.9). The high linkage disequi-
librium (LD) between SNPs and an HLA-DRB1 challenged the result interpretation. When 
the SNPs and HLA-DRB1 alleles were analyzed together, independent association was 
observed for four SNPs in the HLA-DRA/BTNL2 region: rs3135365 (NL; P = 0.015), 
rs3177928 (NL; P < 0.001), rs6937545 (LS; P = 0.012), and rs5007259 (disease activity; 
P = 0.002). These SNPs act as expression quantitative trait loci (eQTL) for HLA-DRB1 
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and/or HLA-DRB5. In conclusion, we found novel SNPs in BTNL2 and HLA-DRA regions 
associating with sarcoidosis. Our finding further establishes that polymorphisms in the 
HLA-DRA and BTNL2 have a role in sarcoidosis susceptibility. This multi-population study 
demonstrates that at least a part of these associations are HLA-DRB1 independent 
(e.g., not due to LD) and shared across ancestral origins. The variants that were 
independent of HLA-DRB1 associations acted as eQTL for HLA-DRB1 and/or -DRB5, 
suggesting a role in regulating gene expression.
Keywords: BTNL2, snP, DRB1, hla, prognosis, sarcoidosis, major histocompatibility complex, haplotype
inTrODUcTiOn
Sarcoidosis (MIM 609464) is a multiorgan inflammatory disor-
der of unknown etiology. The majority of the sarcoidosis patients 
(of European descent) have a favorable prognosis if involvement 
is solely pulmonary, but the clinical picture and prognosis vary 
(1). Current understanding views sarcoidosis primarily as a 
multifactorial disorder with heritability estimates up to 66%, with 
possible environmental triggers in addition to the susceptibility 
gene(s) (2–4).
Sarcoidosis is manifested by accumulation of activated CD4-
positive T  lymphocytes and macrophages at disease sites sug-
gesting a functional role for antigen-presenting molecules and 
immune mediator genes (4). The search for genetic components, 
indicated on the basis of family and multi-ancestral studies 
(2, 5), has shown a strong role of the major histocompatibility 
complex (MHC) region at chromosome 6p21.3 in susceptibility 
to sarcoidosis. Recently, several genome-wide association studies 
have indicated other regions of interest as well (6–8), but none as 
influential as the MHC.
Clinical manifestations in sarcoidosis range from asympto-
matic disease to severe loss-of-function, including an acute dis-
ease (Löfgren’s syndrome), which usually resolves spontaneously, 
a subacute disease, which also may resolve spontaneously or with 
treatment, and a chronic/progressive disease. Associations vary 
from protective to predisposing markers, or markers influenc-
ing clinical outcomes. Thus, previous studies have pointed 
out the importance to characterize patient groups according 
to clinical phenotypes to avoid inconsistency between studies 
(6, 9–12). Associations with sarcoidosis also vary between dif-
ferent ancestral groups. Most classical examples being strong 
association found between HLA-DRB1*03 and Löfgren’s syn-
drome in caucasian populations, whereas among the Japanese, 
this association is absent due the lack of HLA-DRB1*03 allele in 
the population (11).
The most probable pathophysiology of sarcoidosis, the dysreg-
ulation of the immune response (13), strongly suggests benefits 
from a better understanding of the role of the immune-mediating 
genes in sarcoidosis susceptibility. Based on the robust evidence 
of the MHC class III gene association to sarcoidosis, this par-
ticular region warrants further investigation. Probably, the most 
investigated variant in the MHC class III, the splice-site SNP in 
BTNL2 (OMIM 606000) gene (rs2076530 G>A), has so far shown 
contradictory results with different sarcoidosis phenotypes and 
populations (7, 14–16).
Here, we present results from a Finnish case-control discovery 
sample as well as three independent replication studies from the 
Swedish, Dutch, and Czech populations. Our aim was to investi-
gate genetic variance and phenotype specific variants in five func-
tional candidate genes: lymphotoxin alfa (LTA; OMIM 153440), 
tumor necrosis factor (TNF; OMIM 191160), advanced glyco-
sylation end product-specific receptor (AGER; OMIM 600214), 
butyrophilin-like 2 (BTNL2; OMIM 606000), and HLA-DR alpha 
(HLA-DRA; OMIM 142860) within the MHC classes III and II 
with tag-SNP genotyping approach. We also address the ques-
tion whether the tag-SNP associations were due to the strong 
linkage disequilibrium (LD) with HLA-DRB1. Replication of 
gene variants predisposing to disease and disease phenotypes 
in several European populations would indicate their important 
role in disease development.
PaTienTs anD MeThODs
Patients and control subjects
Total of 805 sarcoidosis patients and 870 controls were included 
in the study. The discovery sample set consisted of 188 Finnish 
sarcoidosis patients and 150 Finnish healthy controls. Swedish 
(cases = 219, controls = 360), Dutch (cases = 180, controls = 180), 
and Czech (cases =  218, controls =  180) data sets were used 
for the replication and the joint analysis. In quality control, 40 
sarcoidosis patients (1 Finnish, 29 Swedish, 10 Czech) and 11 
controls (2 Swedish, 2 Czech, 7 Dutch) were excluded due to low 
quality of genotyping results.
Table 1 shows the sample characteristics. Although we had no 
age matched controls to the patients, the controls were unrelated 
healthy individuals recruited from the same geographic and 
ancestral background as the cases. More detailed sample char-
acteristics and DNA extraction have been previously reported 
(10, 12, 17–19). Briefly, in the Finnish discovery sample, the 
patients were recruited from 17 pulmonary units throughout 
the country. The control population consisted of voluntary 
Finnish subjects attending a health survey, representing the 
Finnish population. The Swedish patients were recruited from 
single center, Karolinska University Hospital, Solna, Sweden. The 
control group consisted of consecutively collected Scandinavian 
blood donors. The Czech cases were gathered from the Olomouc 
University Hospital, Olomouc, Czech Republic, and controls were 
Czech nationality blood donors from the same region. The Dutch 
patients with sarcoidosis were from the St. Antonius Hospital, 
Nieuwegein, Netherlands. The control subjects comprised of 
healthy, Dutch Caucasian employees of the St. Antonius Hospital, 
and blood donors from Sanquin blood bank in the Netherlands. 
In all four study populations, the DNA was extracted from the 
buffy coat fraction of whole blood samples.
TaBle 1 | sample characteristics.
nl sarcoidosis subgrouping after 2 years
Total (n) Total (n) 
in genetic 
analysis
individuals 
with nl 
(%)
individuals 
with resolved 
sarcoidosis 
(nlr) (%)
individuals 
with persistent 
sarcoidosis (nlP) (%)
individuals with 
no subgroup info 
available (%)
individuals 
with ls 
(%)
Discovery sample
Finland Sarcoidosis patients 188 187 89.8 42.2 47.6 0.0 10.2
Controls 150 150
replication sample
Sweden Sarcoidosis patients 219 190 58.9 17.4 39.5 2.1 41.1
Controls 360 358
Dutch Sarcoidosis patients 180 180 100.0 50.0 50.0 0.0 0.0
Controls 180 173
Czech Sarcoidosis patients 218 208 81.3 22.6 39.9 18.8 18.8
Controls 180 178
combined discovery and replication sample
Total samples Sarcoidosis patients 805 765 82.2 32.5 44.1 5.6 17.8
Controls 870 859
The non-Löfgren sarcoidosis patients (NL) were subphenotyped into those with the disease resolved within 2 years (NLR) and those with persisting activity at that time point (NLP). 
Patients with Löfgren syndrome (LS) were not subgrouped.
n, number of subjects used in the SNP analysis (initial number of subjects).
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Disease activity was determined using the generally 
accepted WASOG (World Association of Sarcoidosis and Other 
Granulomatous diseases) criteria. The sarcoidosis patients had 
been followed for at least 2  years and further subdivided into 
those with a resolved (normalized radiography and pulmonary 
lung function; no signs of active extrapulmonary disease) or a 
non-resolved disease (persistence of chest radiographic changes 
with clinical signs of disease activity). The resolution threshold 
in the Finnish, Swedish, and Czech populations was 2 years but 
4 years in the Dutch. The patients were grouped into those with 
Löfgren’s syndrome [Löfgren syndrome (LS); n = 136] and non-
Löfgren’s syndrome patients (NL; n = 629). Dutch cohort did not 
contain LS patients.
NL patients were grouped into those with a non-active disease 
[NL resolved (NLR); n = 249] and those with persisting activity 
at that time point [NL persistent (NLP); n =  337]. Forty-three 
patients (5.6%) had no subgroup information available, and we 
excluded them from the subgroup analysis. Due to small sample 
size, the LS patients were not subgrouped based on the disease 
activity.
All the subjects were of European descent and gave their writ-
ten informed consent to participate in the genetic association 
study. The local Ethics Committee of the Department of Internal 
Medicine, Hospital District of Helsinki and Uusimaa, Finland 
approved the study protocol.
genotyping
We selected MHC gene regions of HLA-DRA, LTA, TNF, 
AGER, and BTNL2 for SNP analysis and used the SNP tagging 
approach to identify a SNP or a set of SNPs associating with the 
trait. The tag-SNPs reduce the number of SNPs needed to cover 
the selected region and are chosen from the HapMap database. 
Information about the validation status, tagging quality, minor 
allele frequency (MAF) (>0.01), and gene structure was used 
for selecting the SNPs. In addition to HapMap database, the 
public dbSNP1 database was used to select additional SNPs. 
Eventually, 89 SNPs tagging two 100 and 92 SNP variants were 
genotyped in the Finnish discovery sample [r2 > 0.8; HapMap3 
(20)]. The detailed information for SNP genotypes is provided 
in Table S1 in Supplementary Material. In the replication stage, 
16 of the 89 SNPs (Table 2) were genotyped in the Swedish, 
Dutch, and Czech samples (Table S2 in Supplementary 
Material). Thirteen of the 16 SNPs were selected based on 
unadjusted P-values of P < 0.05 found in the discovery sample 
and only one SNP from each LD block (r2 < 0.8) were chosen. 
In addition, three SNPs (rs1800624, rs3130349, rs3135365) 
were included based on the published studies (14) showing 
sarcoidosis association.
We did assays designing with AssayDesign software and 
performed the multiplex PCR and the iPLEX reaction using 
9–10 ng of DNA as a template. The SNP allele separation based 
on the differences of the single base extension products used the 
Sequenom MassArray iPLEX system (Sequenom, San Diego, CA, 
USA). The HLA-DRB1 genotypes for the samples were previously 
published (10, 12, 18) including genotypes for 497 cases and 517 
controls.
statistical analysis
We compared allele frequencies of 89 SNPs of the discovery 
sample and of 16 SNPs of the replication samples between differ-
ent groups (NL vs. controls, LS vs. controls, NL resolved vs. NL 
persistent) by a case-control association analysis (Chi-square χ2 
test, PLINK software) (21) (Table S2 in Supplementary Material). 
1 http://www.ncbi.nlm.nih.gov/projects/SNP.
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We applied the following quality control filters: minimum call 
rate per sample of 90%, SNP MAF >0.01, and Hardy–Weinberg 
equilibrium >0.001. Total success rate for accepted SNP arrays 
was 99% in the discovery sample and 98% in the replication 
samples together.
We combined the results from SNP analyses of the discovery 
and replication samples for a joint analysis using the random effects 
model (PLINK software). We used the Benjamini–Hochberg False 
Discovery Rate method for correction for multiple testing. SNP 
associations and HLA-DRB1 alleles were adjusted for sex, and all 
the HLA-DRB1 alleles by a logistic regression [PAWStatistics 18.0, 
PLINK software (21)].
To determine the genetic relationships among individuals 
belonging to four different European populations (Finnish, 
Swedish, Dutch, and Czech), we performed principal coordi-
nates analyses (PCoA), a multivariate technique, using pairwise 
individual-by-individual linear genetic distance matrix with 
covariance standardized method in GenAlEx 6.5 tool. This 
linear genetic distance approach correlates genetic and geo-
graphic distances (Mantel test) within the dataset of 16 SNPs 
in healthy control subjects and sarcoidosis patients across the 
studied European populations. The method identified the major 
variation axis within our multidimensional genotype data set. 
As each successive axis explained proportionately less of the 
total genetic variation, the first two axes were used to reveal the 
major separation among individuals. Heterogeneity between 
the studies was evaluated using the I2 metric with a heterogeneity 
threshold of I2 < 25% (low heterogeneity) (22). The haplotypes 
were constructed and pairwise LD (r2) detected using SNP 
Haploview software (23). The LD structure in control samples 
from all study populations was compared to the LD structure of 
population genotype data originating from Phase 3 of the 1,000 
Genomes Project (24). We estimated HLA-DRB1-SNP haplotype 
frequencies from allele data using the Bayesian method with 
PHASE v. 2.1.1 (23). The HLA-DRB1 low-resolution data (HLA-
DRB1*01, *03, *04, *07 *08, *10, *11, *12, *13, *14, *15, *16) was 
available for the Finnish (n = 187 cases, n = 150 controls), and 
for a part of the Swedish (n = 184 cases, n = 187 controls) and 
Czech (n = 90 cases, n = 180 controls) samples. The HapMap3 
proxy SNPs (r2  >  0.8) were detected using SNAP software 
(25, 26). We followed the STREIS principles in immunogenomic 
data analysis (27).
analysis of expression Quantitative  
Trait loci (eQTl) Data and Pathway 
connectivity analysis
To further investigate the possibly functional effects of the signifi-
cant SNPs, we used GENe Expression Variation (GeneVar) (28) 
database to study the eQTL.
resUlTs
A total of 805 sarcoidosis patients and 870 controls were 
included in this study. The discovery sample set consisted of 
Finnish sarcoidosis patients and controls. Swedish, Dutch, and 
Czech data sets were the replication samples and used for the 
FigUre 1 | HLA-DRB1-snP haplotype frequencies. HLA-DRB1 data were available for Finnish, Swedish, and Czech samples. Subjects with missing SNP 
genotype were excluded from the analysis. SNP order is the same as in the Table 2. The analysis shows population-specific differences in haplotype structures. 
Haplotype frequencies (2n) > 0.01 are presented.
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joint analysis. We analyzed 89 SNPs for the discovery samples 
and selected 16 of these SNPs for the replication and the joint 
analysis.
Thirteen snPs showed association with 
sarcoidosis in the Discovery sample
Seven SNPs showed association (uncorrected P  <  0.05) with 
NL in the discovery sample (Table 2). The strongest association 
with NL was observed for rs3177928 (P =  0.001, OR =  2.17) 
located within downstream of HLA-DRA. Four SNPs in BTNL2 
showed significant association with NL, of these, the most 
significant rs28362677 (P =  0.002, OR =  1.92) was a missense 
variant (Ser360Gly). Two SNPs (rs5007259 in BTNL2 promoter 
and rs6937545 in downstream of HLA-DRA) associated with 
LS. Six SNPs [rs9268528 (BTNL2 promoter), rs3135351, and 
rs3129843 (between genes HLA-DRA and BTNL2), rs9268644 
and rs3129877 (HLA-DRA intronic), rs6937545 (downstream of 
HLA-DRA)] were associated with the disease course of sarcoido-
sis (Table 2). Neither TNF nor LTA variants were significant in the 
discovery sample or showed strong LD with other MHC variants, 
hence, not included in the replication stage. For discovery stage, 
detailed results of the allele frequencies from 89 SNPs are found in 
Table S1 in Supplementary Material.
shared and Population-specific snP 
associations with sarcoidosis in the 
replication samples
Heterogeneity at association level was observed among the 
samples and BTNL2 SNPs showed population-specific differences 
(Table S2 in Supplementary Material). The sarcoidosis-associated 
BTNL2 missense SNP rs2076530 (16) and BTNL2 promoter SNP 
rs5007259 were associated in Swedish (rs2076530 with borderline 
association) and Czech samples (NL vs. controls), but were not 
replicated in the Dutch sample. In Dutch samples, the most 
significant exonic BTNL2 SNP rs28362677 (NL 93% vs. controls 
83%; P = 0.00016, OR = 2.5) was not replicated among Swedish 
and Czech samples.
Pcoa for Population stratification
Due to different European origins, the samples were checked for 
ancestral homogeneity using the PCoA. In all study populations, 
the healthy control subjects seemed to be more diverse than the 
sarcoidosis patients. The Finnish and Czech healthy controls were 
most diverged, while Czech and Swedish sarcoidosis patients 
were among least diverged. Overall, a homogenous clustering 
with absence of any major cluster(s) among the individuals and 
TaBle 3 | Disease associated snPs in the major histocompatibility 
complex region in the joint analysis (Finnish, swedish, Dutch, and czech) 
and associations after adjusting for HLA-DRB1 low-resolution alleles.
Unadjusted adjusted for 
HLA-DRB1
snP location P Or P Or
nl vs. c
Rs1800684 AGER (coding) 0.003 0.727
Rs2076530 BTNL2 (coding) <0.001 1.339
rs3763313 BTNL2 (5′) <0.001 1.633
rs3135365 0.009 0.777 0.015 2.15
rs3129877 HLA-DRA (intronic) 0.020 0.819
rs3135392 HLA-DRA (intronic) 0.0058 0.805 <0.001 2.19
rs3177928 HLA-DRA (3′) <0.001 1.898
aHLA-DRB1*15/*16
ls vs. c
rs3130349 RNF5 (coding) <0.001 0.3925
rs1800624 PBX2 (3′) 0.00125 1.6955
rs2076530 BTNL2 (coding) 0.008553 1.4486
rs3763313 BTNL2 (5′) <0.001 2.0534
rs5007259 BTNL2 (5′) <0.001 1.9936
rs3129843 <0.001 3.4443
rs9268644 HLA-DRA (intronic) 0.0009935 1.6901
rs6937545 <0.001 2.2837 0.012 3.49
aHLA-
DRB1*03/*13/*14
nlr vs. nlP
rs28362677 BTNL2 (coding) 0.004712 0.5743
rs3135351 0.003817 1.5283
rs3129843 0.002962 1.8574
rs3129877 HLA-DRA (intronic) 0.004781 1.4506
aAssociated HLA-DRB1 allele(s).
NL, non-Löfgren sarcoidosis patient; LS, Sarcoidosis patient with LS; NLR, non-
Löfgren with resolved disease; NLP, non-Löfgren with persistent disease; C, controls.
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low percent of variations was determined (Figures S1 and S2 in 
Supplementary Material).
Joint analysis combining results from 
Discovery and replication samples
The allelic associations found in the discovery and replication 
samples (after filtering, 765 sarcoidosis patients and 859 controls) 
were used for the joint analysis. Four of the SNPs were replicated 
in all four populations: rs3763313 (NL vs. C; BTNL2 upstream-
variant), rs3177928 (NL vs. C; HLA-DRA downstream variant), 
rs5007259 (L vs. C; BTNL2 upstream-variant), and rs6937545 
(L vs. C; HLA-DRA downstream variant).
In the joint analysis, all the other SNPs (P-value for random 
effects < 0.05), except rs9268528, were associated with at least one 
of the disease phenotypes (I2 < 25%) (Table S2 in Supplementary 
Material). Seven SNPs in AGER, BTNL2, and HLA-DRA associ-
ated with NL, two most significant being downstream variant of 
HLA-DRA (rs3177928, P =  0.0000002, OR =  1.9) and BTNL2 
promoter SNP (rs3763313, P = 0.000001, OR = 1.6). Eight SNPs 
associated with LS (Table S2 in Supplementary Material). Three 
of these SNPs had P <  10−8: rs3130349 in AGER (OR =  0.39), 
rs3129843 between genes BTNL2 and HLA-DRA (OR = 3.4), and 
rs6937545 in HLA-DRA (OR = 2.3). Fifty-seven percent (78/136) 
of LS patients were Swedish. Five SNPs were associated with the 
disease course of sarcoidosis (BTNL2 exonic SNP rs28362677, 
BTNL2 promoter SNP rs5007259, SNPs rs3135351 and rs3129843 
between genes BTNL2 and HLA-DRA, and HLA-DRA down-
stream SNP rs3129877) (Table S2 in Supplementary Material). 
All the associations, except rs5007259 in NLR vs. NLP, remained 
significant after correcting for multiple comparisons (Table S2 in 
Supplementary Material).
haplotype analysis showed  
Population-specific structures
Haplotype analysis was concordant with the single allele findings 
showing that population-specific structures occur (Figure  1). 
Haplotype 1 with HLA-DRB1*01 was more common in the 
Finnish sample (cases 6%, controls 14%) than in the Swedish 
(cases 3%, controls 8%) or the Czech sample (cases 3%, controls 
5%). The haplotype 3 with HLA-DRB1*03 was the most frequent 
haplotype in the Swedish sample (cases 19%, controls 12%) prob-
ably due to the high number of LS patients that commonly share 
the allele. Haplotype 28 with HLA-DRB1*16 was missing or rare 
in the Finnish and Swedish sample.
HLA-DRB1-independent association  
in Four snPs
Addressing the question of whether the SNP associations were 
secondary to the HLA-DRB1 associations found previously 
(10, 12, 18, 29), we performed logistic regression adjusting for the 
low-resolution HLA-DRB1 alleles (Table 3). In the comparisons of 
“NL vs. controls (recessive model),” SNPs rs3135365 and rs3177928, 
HLA-DRB1*15 and *16 were suggested as independent variants 
(P = 0.015, OR = 2.15, CI 95% = 1.16–3.99; P < 0.001, OR = 2.19, 
CI 95% = 1.54–3.15; P < 0.001, OR = 3.49, CI 95% = 1.87–6.53, 
P = 0.044, OR = 0.43, CI 95% = 0.19–0.98; respectively). For LS 
using a dominant model, the downstream SNP of HLA-DRA 
(rs6937545; P =  0.012, OR =  3.49, CI 95% =  1.32–9.25) and 
HLA-DRB1*03 (P < 0.001, OR = 4.67, CI 95% = 2.18–10.12), *13 
(P = 0.034, OR = 2.41, CI 95% = 1.07–5.42), and *14 (P = 0.007, 
OR = 5.38, CI 95% = 1.59–18.2) alleles were suggested as signifi-
cant predisposing markers. In the analysis of NLR vs. NLP (reces-
sive model), no independent associations were detected in studied 
SNPs. None of the AGER SNPs remained significant after adjusting 
for HLA-DRB1 alleles showing strong LD with HLA-DRB1.
lD structure confirmed snP selection 
strategy
Figures 2–4 visualize genotyped SNPs (P < 0.05 and I2 < 25%) 
and the LD structure (r2) based on HapMap data for both cases 
and controls. Estimated recombination rates are plotted to show 
the LD structure around the associated SNPs. Gene annotations 
were adapted from the University of California at Santa Cruz 
Genome Browser.2 As none of the genotyped SNPs had strong 
(r2 >  0.8) pairwise LD in this study, it confirmed the selection 
2 http://genome.ucsc.edu/.
FigUre 2 | The meta-analysis of non-löfgren sarcoidosis (nl) vs. controls with Finnish, swedish, Dutch, and czech samples. The linkage 
disequilibrium (LD) information (r2) is shown by color-coded dots and the recombination rates where the peaks are the hotspots are based on the HapMap data.  
The LD structure (r2) in the current study for the top significant SNPs (I2 < 25) are shown on the right. After adjusting for HLA-DRB1 alleles, the SNPs that  
remained significant are pointed with an arrow.
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strategy where only one SNP from each LD block was genotyped. 
LD structure of control populations corresponded to the 1,000 
Genomes population data (data not shown).
Four snPs act as local eQTl  
for HLA-DRB1/-DRB5
Using the GeneVar database (28), we analyzed the available 
eQTL-SNP-gene data to identify eQTL genes surrounding inde-
pendent SNPs [lymphoblastoid cell lines, CEU (30)]. The analysis 
suggested SNPs rs3135365, rs3177928, and rs6937545 act as 
cis-acting eQTL for HLA-DRB1, and rs3135365, rs6937545, and 
rs5007259 act as eQTL for HLA-DRB5. Figure S3 in Supplementary 
Material presents the SNP-probe association plots.
DiscUssiOn
Major histocompatibility complex region contains immune 
mediator genes that have showed either predisposing or protec-
tive effects to sarcoidosis (12, 15). Here, we report a set of 16 
SNPs located in the MHCs that are associated with sarcoidosis 
and shared between four European populations with distinct 
ancestral origins (Finnish, Swedish, Dutch, and Czech). Only two 
of these SNPs have been previously associated with sarcoidosis. 
After conditioning with HLA-DRB1 alleles, three of the 16 SNPs 
remained independently associated with sarcoidosis.
We identified two novel HLA-DRA downstream variants that 
were independent of HLA-DRB1 alleles: rs3177928 associated 
with NL and rs6937545 associated with LS. In a high-density 
genetic mapping study of extended MHC region in four European 
populations and one black African descent population, NL 
sarcoidosis showed similar association pattern: main associa-
tions were found in variants located in the MHC class II region 
(31). MHC II region associations were found in LS patients as 
well. Recent non-sarcoidosis studies showed that rs3177928 
was associated with lipoprotein metabolism (32) and connected 
with inflammatory mechanisms (33–35). HLA-DRA encodes the 
α-subunit of the HLA-DR cell surface receptor and expresses on 
antigen-presenting cells. HLA-DRA shows strong LD structure 
FigUre 3 | The meta-analysis of löfgren (ls) vs. controls with Finnish, swedish, and czech samples. The linkage disequilibrium (LD) information (r2) is 
shown by color-coded dots and the recombination rates where the peaks are the hotspots are based on the HapMap data. The LD structure (r2) in the current study 
for the top significant SNPs (I2 < 25) are shown on the right. After adjusting for HLA-DRB1 alleles, the SNPs that remained significant are pointed with an arrow.
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and its variants regulate the expression of other MHC genes (36). 
Both rs3177928 and rs6937545 are also cis-acting eQTL affect-
ing the expression of HLA-DRB1 and are not in LD with other 
HLA-DRA gene variants previously associated with sarcoidosis 
(6–8). Interestingly, HLA-DRA has shown to have SNP–SNP (8) 
interaction with ANXA11, another sarcoidosis associated gene. 
ANXA11 has an essential role in cell division and apoptosis (6, 7).
The increasing line of evidence suggests that BTNL2, a member 
of the immunoglobulin gene superfamily, is a key element for sar-
coidosis predisposition (6, 15, 16, 37). BTNL2 regulates T cells and 
is expressed on dendritic cells (15, 38). Here, the novel variant in 
BTNL2 5’ region associated independently with distinct sarcoido-
sis phenotype (rs3135365 with NL) supporting the importance of 
the BTNL2 promoter region in sarcoidosis disease development. 
Several other BTNL2 SNPs also reached the level of significance. 
However, they showed either heterogeneity between populations 
(e.g., exonic SNP rs28362677 and 5’ upstream SNP rs5007259) or 
the association weakened after adjustments with HLA-DRB1, as 
occurred with the splice-site variant of BTNL2 (rs2076530) that 
was previously associated with chronic sarcoidosis in subjects of 
European descent (6, 16, 30, 37, 39–41). The strong LD between 
BTNL2 and HLA-DRB1 complicates the interpretation of the 
results and the inconsistency with previous studies may be due to 
differences in the study design (heterogeneity in diagnosis) and 
population origin (16, 42, 43). Given that, we suggest that district 
variants of BTNL2 are present only in certain populations, like 
exonic SNP rs28362677 in the Dutch sample that may explain the 
lack of replication of rs2076530 (11, 40). Fine-mapping studies of 
BTNL2 in large multi-population sample would shed light on the 
allelic heterogeneity of BTNL2.
HLA allele variation in Europe follows the North to Southeast 
axis and as expected, different HLA haplotype profiles were 
observed in this study (44). We noticed that the use of different 
population data was advantageous for the HLA-DRB1 adjust-
ments, because the populations have different chromosomal 
regions where LD breaks down as well as distinct allele frequen-
cies (4). HLA-DRB1*03 has been associated with sarcoidosis 
with favorable prognosis and Löfgren’s syndrome in several 
populations with European descent, especially in Scandinavian 
countries (10, 39, 45–47). In Japan, the HLA-DRB1*03 allele is 
rare, explaining the non-association of the variant with sarcoido-
sis (48). We showed that LS-associated SNPs were inherited as a 
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FigUre 4 | The meta-analysis of sarcoidosis subgroups (resolved sarcoidosis, nlr vs. persistent sarcoidosis, nlP) with Finnish, swedish, Dutch, 
and czech samples. The linkage disequilibrium (LD) information (r2) is shown by color-coded dots and the recombination rates where the peaks are the hotspots 
are based on the HapMap data. The LD structure (r2) in the current study for the top significant SNPs (I2 < 25) are shown on the right. After adjusting for HLA-DRB1 
alleles, the SNPs that remained significant are pointed with an arrow.
conserved block with the HLA-DRB1*03, especially in the Swedish 
sample (10), and after conditioning with HLA-DRB1 alleles, only 
one SNP remained significant (rs6937545 in HLA-DRA down-
stream). Given the strong LD within MHC genes, we highlight 
the importance to use of HLA genotypes in addition to SNP data 
when aiming to pinpoint the causal variants within MHC region.
There are several strengths in our study. The sample size in the 
joint analysis of the discovery and replication sets was relatively 
large for case-control study in the context of sarcoidosis and its 
incidence. Our fine-mapping strategy of MHC candidate genes 
in different ancestral origins aimed to detect variants associated 
with different disease phenotypes shared in different populations. 
Previous studies have pointed out that the precise clinical charac-
terization of the patients is essential, because sarcoidosis is a highly 
heterogeneous disease. To overcome the disease heterogeneity, we 
subdivided the patients according to clinical phenotypes (49, 50).
In conclusion, we found novel SNPs in BTNL2 and HLA-DRA 
regions associating with sarcoidosis. Our finding further estab-
lishes that polymorphisms in the HLA-DRA and BTNL2 have a 
role in sarcoidosis susceptibility. This multi-population study 
demonstrates that at least a part of these associations are HLA-DRB1 
independent (e.g., not due to LD), and shared across ancestral 
origins. The variants that were independent of HLA-DRB1 associa-
tions, acted as eQTL for HLA-DRB1 and/or -DRB5, suggesting a 
role in regulating gene expression. Future functional studies with 
larger sample are required to reveal the causal regulatory variation 
at this locus and the immunogenetic basis related to sarcoidosis.
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